• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT MAGNA PERICARDIAL BIOPROSTHESIS; REPLACEMENT, HEART-VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT MAGNA PERICARDIAL BIOPROSTHESIS; REPLACEMENT, HEART-VALVE Back to Search Results
Model Number 3000
Medical Device Problem Codes Calcified (1077); Insufficient Device Problem Information (3190)
Health Effect - Clinical Codes Heart Failure/Congestive Heart Failure (4446); Insufficient Information (4580)
Date of Event 05/23/2025
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
H10: additional manufacturer narrative: the subject device is not available for evaluation, as it remains implanted in the patient.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Event or Problem Description
It was reported that a patient with a 23mm 3000 aortic valve, underwent a valve-in-valve procedure after an implant duration of 8 years, 7 months due to unknown reason.The tavr was successfully performed with a 23mm 9755rsl valve.
 
Additional Manufacturer Narrative
Svd is a logical and expected consequence of the chemical, mechanical, and immunological processes associated with bhv implantation.The common endpoint of all these factors is calcification and degradation.Svd is an acquired condition, intrinsic to bioprosthetic valves, characterized by deterioration of the leaflets or supporting structures, leading to thickening, calcification, tearing, or disruption of the prosthetic valve materials.These changes result in valvular dysfunction manifesting as stenosis and/or regurgitation with a consequent drop in hemodynamic efficacy of the valve.Despite the advancements in the heart valve industry, svd commonly begins 7- 8 years after implantation, with a considerably increased rate in patients with pertinent comorbidities and/or an implant duration of greater than 10 years.Prior investigations and extensive literature review have shown that svd is predominantly related to patient factors and implant duration rather than to manufacturing issues.Events related to device design, manufacturing, or use error tend to manifest at an earlier implant duration.The instructions for use (ifu) have been reviewed, and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.The reported type of event is included in the ifu.There is no evidence to suggest a manufacturing defect caused or contributed to the reported event.Based on the information available, the most likely root cause is patient factors, including an implant duration of 7 or more years, chronic kidney disease (ckd) and coronary artery disease (cad).
 
Additional Manufacturer Narrative
H10: additional manufacturer narrative: updated sections: b5, b7, g3, g6, h2, h6 (component code, clinical code, device code).
 
Event or Problem Description
It was reported that a patient with a 23mm 3000 aortic valve, underwent a valve-in-valve procedure after an implant duration of 8 years, 7 months due to calcification leading to stenosis.The patient presented with heart failure and shortness of breath.The tavr was successfully performed with a 23mm 9755rsl valve.The patient was stable post-procedure and was discharged on pod #4.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CARPENTIER-EDWARDS PERIMOUNT MAGNA PERICARDIAL BIOPROSTHESIS
Common Device Name
REPLACEMENT, HEART-VALVE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
saurav singh
1 edwards way
mle fl2- office m2013
irvine, CA 92614
9492506615
MDR Report Key22235115
Report Number2015691-2025-04926
Device Sequence Number8976811
Product Code DYE
UDI-Device Identifier00690103162257
UDI-Public(01)00690103162257(17)200707
Combination Product (Y/N)N
Initial Reporter StateAR
Initial Reporter CountryUS
PMA/510(K) Number
P860057
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2016
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Health Professional,User Facility,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date (Section B) 07/22/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date07/07/2020
Device Model Number3000
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 05/23/2025
Supplement Date Received by Manufacturer06/25/2025
07/21/2025
Initial Report FDA Received Date06/17/2025
Supplement Report FDA Received Date07/16/2025
07/22/2025
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured07/08/2016
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Life Threatening; Required Intervention; Hospitalization;
Patient Age66 YR
Patient SexMale
-
-